In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats

Bakker, Willem H.; Krenning, Eric P.; Reubi, Jean–Claude; Breeman, W. A. P.; Setyono-Han, Buddy; Jong, Marion de; Kooij, P. P. M.; Berthou, Christian; Hagen, P. Martin van; Marbach, Peter; Visser, Theo J.; Pless, J.; Lamberts, Steven W. J.

doi:10.1016/0024-3205(91)90053-e

Cited by 156 publications

(82 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of tomography (SPECT) was reported to improve the detection of insulinomas: 80% were detected in a study about 14 patients with insulinoma (9). Pretreatment with octreotide might lead to saturation of somatostatin receptors (36).…”

Section: Discussionmentioning

confidence: 99%

Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies

Vezzosi¹,

Bennet²,

Rochaix³

et al. 2005

eur j endocrinol

164

119

View full text Add to dashboard Cite

Objective: We studied the efficacy of octreotide treatment on hypoglycaemia in patients with insulinoma and its relationships with Octreoscan scintigraphy and the presence of tumoral somatostatin receptors sst2A and sst5. Design and methods: 17 patients with insulinoma were evaluated using (i) evaluation of blood glucose, insulin and C-peptide during a short 100 mg octreotide test in fasting patients and/or treatment over 8 days-8 months with octreotide, (ii) Octreoscan scintigraphy and (iii) immunostaining of the tumor with anti-sst2A and anti-sst5. Results: Octreotide was effective on hypoglycaemia in 10/17 patients. Octreoscan scintigraphy detected 4/17 insulinomas. sst2A receptor was detected in 7/17 insulinomas and sst5 in 15/17 insulinomas. Octreotide was effective on hypoglycaemia in those seven patients with sst2A receptorexpressing insulinoma, and in three patients with undetectable sst2A receptor and detectable sst5; it was ineffective in six patients whose tumor expressed the sst5 receptor with undetectable sst2A and in one patient with undetectable sst2A and sst5 receptor. Conclusions: Octreotide is an effective treatment of hypoglycaemia in more than 50% of patients with insulinoma. Detection of responsive patients was better based on a positive short test with subcutaneous octreotide than on the results of Octreoscan scintigraphy. Positive anti-sst2 receptor immunostaining is associated with efficacy of octreotide treatment, but does not account for all cases of responsiveness to octreotide. Expression of sst5 receptor does not appear to explain per se the efficacy of octreotide on sst2A-negative insulinomas.European Journal of Endocrinology 152 757-767

show abstract

Section: Discussionmentioning

confidence: 99%

Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies

Vezzosi¹,

Bennet²,

Rochaix³

et al. 2005

eur j endocrinol

164

119

View full text Add to dashboard Cite

show abstract

“…In-DTPAOctreotide, D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr[ol]), was successfully used to visualize somatostatin receptor positive tumors by gamma camera scintigraphy in the early 1990s [48][49][50] . Normal physiological uptake is seen in the thyroid, spleen, liver and pituitary due to receptor binding of the peptides, while tracer uptake in the kidneys is predominantly secondary to reabsorption of filtered peptides, and bowel uptake is presumably secondary to hepatobiliary clearance (Figures 6 and 7).…”

mentioning

confidence: 99%

Imaging of gastroenteropancreatic neuroendocrine tumors

Tan

Tan²

2011

WJCO

View full text Add to dashboard Cite

Imaging of gastroenteropancreatic neuroendocrine tumors can be broadly divided into anatomic and functional techniques. Anatomic imaging determines the local extent of the primary lesion, providing crucial information required for surgical planning. Functional imaging, not only determines the extent of metastatic disease spread, but also provides important information with regard to the biologic behavior of the tumor, allowing clinicians to decide on the most appropriate forms of treatment. We review the current literature on this subject, with emphasis on the strengths of each imaging modality.

show abstract

“…Although SST-14 or SST-28 show binding to SSTR with similar affinity, the octapeptide analogs display high affinity to SSTR2 and SSTR5, moderate affinity to SSTR3, and have only poor binding to SSTR1 and SSTR4 (9,14,18). Based on the findings that various neuroendocrine malignancies and many other solid tumors such as breast, lung, renal, pancreatic, gastric, colon cancers, and brain tumors as well as androgenindependent metastatic adenocarcinoma of the prostate express SSTR2 and͞or SSTR5 (3,9,(13)(14)(15)(16)(17)(18)(19)(20)(21)(22), radiolabeled octapeptide analogs were designed for autoradiographic detection of such tumors and their metastases (3,7,23,24). Thus,…”

mentioning

confidence: 99%

Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin

Nagy

Schally

Halmos

et al. 1998

Proc. Natl. Acad. Sci. U.S.A.

133

104

View full text Add to dashboard Cite

show abstract

In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats

Cited by 156 publications

References 7 publications

Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies

Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies

Imaging of gastroenteropancreatic neuroendocrine tumors

Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin

Contact Info

Product

Resources

About